Lack of intent evidence dooms drugmaker fine

Ruling that Switzerland’s antitrust authority failed to provide sufficient evidence of anticompetitive intent, a Swiss court has found that Pfizer, Eli Lilly, and Bayer are no longer guilty of illegally setting minimum prices for their erectile dysfunction medication.

Get unlimited access to all Global Competition Review content